反应详情

2-Hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetic acid (Int-Va, 50 mg, 0.116 mmol), 5-(aminomethyl)-2-methylpyrimidin-4-amine-2 HCl (36.7 mg, 0.174 mmol), 4-methylmorpholine (46.9 mg, 0.464 mmol), and HATU (57.3 mg, 0.151 mmol) were added to DMF (2 mL). The mixture was stirred for 1 h. Methanol was added and the mixture was filtered for prep HPLC. It was purified by prep HPLC (PHENOMENEX® Luna 5u 21.2×100 mm, gradient elution with Method 1—MeOH/water containing 0.1% trifluoroacetic acid as defined above, 0% B to 100% B over 10 min, 20 mL/min, 220 nM, product retention=11.2 min) to provide single enantiomer N-((4-amino-2-methylpyrimidin-5-yl)methyl)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide (45 mg, 0.078 mmol, 67.6% yield): LCMS=552.3 [M+H]+; 1H NMR (400 MHz, methanol-d4) δ ppm 8.13-8.25 (2 H, m), 7.91 (1 H, s), 7.53-7.75 (7 H, m), 5.21 (1 H, s), 4.20-4.39 (2 H, m), 2.51 (3 H, s); HPLC peak RT=8.3 min (Method A).

1. filtrationthe mixture was filtered for prep HPLC
2. customIt was purified by prep HPLC (PHENOMENEX® Luna 5u 21.2×100 mm, gradient elution with Method 1—MeOH/water containing 0.1% trifluoroacetic acid as defined above, 0% B to 100% B over 10 min, 20 mL/min, 220 nM, product retention=11.2 min)